 |
|
|
REFERENCES
301.
Lotsch J, Zimmermann M, Darimont J, et al: Does
the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide
toxicity? Anesthesiology 97:814–819, 2002.
302.
Osborne R, Joel S, Trew D, Slevin M: Morphine
and metabolite behavior after different routes of morphine administration: demonstration
of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol
Ther 47:12–9, 1990.
303.
Lotsch J, Kobal G, Stockmann A, et al: Lack of
analgesic activity of morphine-6-glucuronide after short-term intravenous administration
in healthy volunteers. Anesthesiology 87:1348–1358, 1997.
304.
Motamed C, Mazoit X, Ghanouchi K, et al: Preemptive
intravenous morphine-6-glucuronide is ineffective for postoperative pain relief.
Anesthesiology 92:55–360, 2000.
305.
Taeger K, Weninger E, Schmelzer F, et al: Pulmonary
kinetics of fentanyl and alfentanil in surgical patients. Br J Anaesth 61:425–434,
1988.
306.
Meuldermans WE, Hurkmans RM, Heykants JJ: Plasma
protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil
in blood. Arch Int Pharmacodyn Ther 257:4–19, 1982.
307.
Shafer A, Sung ML, White PF: Pharmacokinetics
and pharmacodynamics of alfentanil infusions during general anesthesia. Anesth Analg
65:1021–1028, 1986.
308.
Bovill JG, Sebel PS, Blackburn CL, Heykants J:
The pharmacokinetics of alfentanil (R39209): A new opioid analgesic. Anesthesiology
57:439–443, 1982.
309.
Camu F, Gepts E, Rucquoi M, Heykants J: Pharmacokinetics
of alfentanil in man. Anesth Analg 61:657–661, 1982.
310.
Meuldermans W, Hendrickx J, Lauwers W, et al:
Excretion and biotransformation of alfentanil and sufentanil in rats and dogs.
Drug Metab Dispos 15:905–913, 1987.
311.
Kharasch ED, Thummel KE: Human alfentanil metabolism
by cytochrome P450 3A3/4. An explanation for the interindividual variability in
alfentanil clearance? Anesth Analg 76:1033–1039, 1993.
312.
Hudson RJ, Bergstrom RG, Thomson IR, et al: Pharmacokinetics
of sufentanil in patients undergoing abdominal aortic surgery. Anesthesiology 70:426–431,
1989.
313.
Gepts E, Shafer SL, Camu F, et al: Linearity
of pharmacokinetics and model estimation of sufentanil. Anesthesiology 83:1194–204,
1005.
314.
Lavrijsen K, Van Houdt J, Van Dyck D, et al:
Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans. Drug
Metab Dispos 18:704–710, 1990.
315.
Egan TD, Lemmens HJ, Fiset P, et al: The pharmacokinetics
of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.
Anesthesiology 79:881–892, 1993.
316.
Westmoreland CL, Hoke JF, Sebel PS, et al: Pharmacokinetics
of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing
elective inpatient surgery. Anesthesiology 79:893–903, 1993.
317.
Duthie DJ, Stevens JJ, Doyle AR, et al: Remifentanil
and pulmonary extraction during and after cardiac anesthesia. Anesth Analg 84:740–744,
1997.
318.
Buerkle H, Yaksh TL: Continuous intrathecal administration
of shortlasting mu opioids remifentanil and alfentanil in the rat. Anesthesiology
84:926–935, 1996.
319.
Egan TD: Remifentanil pharmacokinetics and pharmacodynamics.
A preliminary appraisal. Clin Pharmacokinet 29:80–94, 1995.
320.
Cox EH, Langemeijer MW, Gubbens-Stibbe JM, et
al: The comparative pharmacodynamics of remifentanil and its metabolite, GR90291,
in a rat electroencephalographic model. Anesthesiology 90:535–444, 1999.
321.
Dershwitz M, Hoke JF, Roscow CE, et al: Pharmacokinetics
and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.
Anesthesiology 84:812–820, 1996.
322.
Hoke JF, Shlugman D, Dershwitz M, et al: Pharmacokinetics
and pharmacodynamics of remifentanil in persons with renal failure compared with
healthy volunteers. Anesthesiology 87:533–541, 1997.
323.
Stiller RL, Davis PJ, McGowan FX, et al: In vitro
metabolism of remifentanil: The effects of pseudocholinesterase deficiency. Anesthesiology
83:A381, 1995.
324.
Shafer SL, Stanski DR: Improving the clinical
utility of anesthetic drug pharmacokinetics. Anesthesiology 76:327–330, 1992.
325.
Hughes MA, Glass PS, Jacobs JR: Context-sensitive
half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.
Anesthesiology 76:334–341, 1992.
326.
Youngs EJ, Shafer SL: Pharmacokinetic parameters
relevant to recovery from opioids. Anesthesiology 81:833–842, 1994.
327.
Vuyk J, Mertens MJ, Olofsen E, et al: Propofol
anesthesia and rational opioid selection: Determination of optimal EC50–EC95
propofol-opioid concentrations that assure adequate anesthesia and a rapid return
of consciousness. Anesthesiology 87:1549–1562, 1997.
328.
Metz C, Gobel L, Gruber M, et al: Pharmacokinetics
of human cerebral opioid extraction: A comparative study on sufentanil, fentanyl,
and alfentanil in a patient after severe head injury. Anesthesiology 92:1559–1567,
2000.
329.
Shafer SL, Varvel JR: Pharmacokinetics, pharmacodynamics,
and rational opioid selection. Anesthesiology 74:53–63, 1991.
330.
Bailey JM: Technique for quantifying the duration
of intravenous anesthetic effect. Anesthesiology 83:1095–1103, 1995.
331.
Egan TD: Intravenous drug delivery systems:
toward an intravenous "vaporizer." J Clin Anesth (Suppl 2):8–14, 1996.
332.
Olkkola KT, Hamunen K, Maunuksela EL: Clinical
pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.
Clin Pharmacokinet 28:385–404, 1995.
333.
Mannering GJ: Drug metabolism in the newborn.
Fed Proc 44:2302–2308, 1985.
334.
Scott JC, Stanski DR: Decreased fentanyl and
alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic
evaluation. J Pharmacol Exp Ther 240:159–166, 1987.
335.
Minto CF, Schnider TW, Egan TD, et al: Influence
of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil.
I. Model development. Anesthesiology 86:10–23, 1997.
336.
Maitre PO, Vozeh S, Heykants J, et al: Population
pharmacokinetics of alfentanil: The average dose-plasma concentration relationship
and interindividual variability in patients. Anesthesiology 66:3–12, 1987.
337.
Egan TD, Huizinga B, Gupta SK, et al: Remifentanil
pharmacokinetics in obese versus lean patients. Anesthesiology 89:562–573,
1998.
338.
Davies G, Kingswood C, Street M: Pharmacokinetics
of opioids in renal dysfunction. Clin Pharmacokinet 31:410–422, 1996.
339.
Osborne R, Joel S, Grebenik K, et al: The pharmacokinetics
of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54:158–167,
1993.
340.
Schochet RB, Murray GB: Neuropsychiatric toxicity
of meperidine. J Intensive Care Med 3:246, 1988.
341.
Davis PJ, Stiller RL, Cook DR, et al: Pharmacokinetics
of sufentanil in adolescent patients with chronic renal failure. Anesth Analg 67:268–271,
1988.
342.
Chauvin M, Lebrault C, Levron JC, Duvaldestin
P: Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 66:53–56,
1987.
343.
Haberer JP, Schoeffler P, Couderc E, Duvaldestin
P: Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth
54:1267–1270, 1982.
344.
Ferrier C, Marty J, Bouffard Y, Haberer JP, et
al: Alfentanil pharmacokinetics in patients with cirrhosis. Anesthesiology 62:480–484,
1985.
345.
Chauvin M, Bonnet F, Montembault C, et al: The
influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved
with an infusion model in humans: Measurement of alfentanil hepatic extraction coefficient.
Anesth Analg 65:999–1003, 1986.
346.
Hudson RJ, Thomson IR, Burgess PM, Rosenbloom
M: Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery.
Can J Anaesth 38:61–67, 1991.
347.
Navapurkar VU, Archer S, Frazer NM, et al: Pharmacokinetics
of remifentanil during hepatic transplantation. Anesthesiology 83:A382, 1995.
348.
Dumont L, Picard V, Marti RA, Tassonyi E: Use
of remifentanil in a patient with chronic hepatic failure. Br J Anaesth 81:265–267,
1998.
349.
Gedney JA, Ghosh S: Pharmacokinetics of analgesics,
sedatives and anaesthetic agents during cardiopulmonary bypass. Br J Anaesth 75:344–351,
1995.
350.
Kentala E, Kaila T, Arola M, et al: Pharmacokinetics
and clinical response of hyoscine plus morphine premedication in connection with
cardiopulmonary bypass surgery. Eur J Anaesthesiol 8:135–140, 1991.
351.
Lunn JK, Stanley TH, Eisele J, et al: High dose
fentanyl anesthesia for coronary artery surgery: Plasma fentanyl concentrations
and influence of nitrous oxide on cardiovascular responses. Anesth Analg 58:390–395,
1878.
352.
Skacel M, Knott C, Reynolds F, Aps C: Extracorporeal
circuit sequestration of fentanyl and alfentanil. Br J Anaesth 58:947–949,
1986.
353.
Okutani R, Philbin DM, Rosow CE, et al: Effect
of hypothermic hemodilutional cardiopulmonary bypass on plasma sufentanil and catecholamine
concentrations in humans. Anesth Analg 67:667–670, 1988.
354.
Hug CC Jr, Burm AG, de Lange S: Alfentanil pharmacokinetics
in cardiac surgical patients. Anesth Analg 78:231–239, 1994.
355.
Hynynen M, Hynninen M, Soini H, et al: Plasma
concentration and protein binding of alfentanil during high-dose infusion for cardiac
surgery. Br J Anaesth 72:571–576, 1994.
356.
Lullmann H, Martins BS, Peters T: pH-dependent
accumulation of fentanyl, lofentanil and alfentanil by beating guinea pig atria.
Br J Anaesth 57:1012–1017, 1985.
357.
Egan TD, Kuramkote S, Gong G, et al: Fentanyl
pharmacokinetics in hemorrhagic shock: A porcine model. Anesthesiology 91:156–166,
1999.
358.
Johnson KB, Kern SE, Hamber EA, et al: Influence
of hemorrhagic shock on remifentanil: A pharmacokinetic and pharmacodynamic analysis.
Anesthesiology 2001; 94:322–332, 2001.
359.
Katz J, Clairoux M, Redahan C, et al: High dose
alfentanil pre-empts pain after abdominal hysterectomy. Pain 68:109–118, 1996.
360.
Woolf CJ, Chong MS: Preemptive analgesia—treating
postoperative pain by preventing the establishment of central sensitization. Anesth
Analg 77:362–379, 1993.
361.
Gottschalk A, Smith DS, Jobes DR, et al: Preemptive
epidural analgesia and recovery from radical prostatectomy: A randomized controlled
trial. JAMA 279:1076–1082, 1998.
362.
Wasylak TJ, Abbott FV, English MJ, Jeans ME:
Reduction of postoperative morbidity following patient-controlled morphine. Can
J Anaesth 37:726–731, 1990.
363.
Upton RN, Semple TJ, Macintyre PE: Pharmacokinetic
optimisation of opioid treatment in acute pain therapy. Clin Pharmacokinet 33:2252–2244,
1997.
364.
Plummer JL, Owen H, Ilsley AH, Inglis S: Morphine
patient-controlled analgesia is superior to meperidine patient-controlled analgesia
for postoperative pain. Anesth Analg 84:794–799, 1997.
365.
Andrews DT, Leslie K, Sessler DI, Bjorksten AR:
The arterial blood propofol concentration preventing movement in 50% of healthy
women after skin incision. Anesth Analg 85:414–419, 1997.
366.
Ebert JP, Pearson JD, Gelman S, et al: Circulatory
responses to laryngoscopy: The comparative effects of placebo, fentanyl and esmolol.
Can J Anaesth 36:301–306, 1989.
367.
Vuyk J, Engbers FH, Burm AG, et al: Pharmacodynamic
interaction between propofol and alfentanil when given for induction of anesthesia.
Anesthesiology 84:288–299, 1996.
368.
Billard V, Moulla F, Bourgain JL, et al: Hemodynamic
response to induction and intubation. Propofol/fentanyl interaction. Anesthesiology
81:1384–1393, 1994.
369.
Kazama T, Ikeda K, Morita K: Reduction by fentanyl
of the Cp50 values of propofol and hemodynamic responses to various noxious stimuli.
Anesthesiology 87:213–227, 1997.
370.
Smith C, McEwan AI, Jhaveri R, et al: The interaction
of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision.
Anesthesiology 81:820–828, 1994.
371.
Van Aken H, Meinshausen E, Prien T, et al: The
influence of fentanyl and tracheal intubation on the hemodynamic effects of anesthesia
induction with propofol/N2
O in humans. Anesthesiology 68:157–163,
1988.
372.
Katoh T, Uchiyama T, Ikeda K: Effect of fentanyl
on awakening concentration of sevoflurane. Br J Anaesth 73:322–325, 1994.
373.
White PF, Coe V, Shafer A, Sung ML: Comparison
of alfentanil with fentanyl for outpatient anesthesia. Anesthesiology 64:99–106,
1986.
374.
From RP, Warner DS, Todd MM, Sokoll MD: Anesthesia
for craniotomy: a double-blind comparison of alfentanil, fentanyl, and sufentanil.
Anesthesiology 73:896–904, 1990.
375.
Kuperwasser B, Dahl M, McSweeney TD, Howie MB:
Comparison of alfentanil and sufentanil in the ambulatory surgery procedure when
used in balanced anesthesia technique. Anesth Analg 67:S122, 1988.
376.
Glass PS, Doherty M, Jacobs JR, et al: Plasma
concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision.
Anesthesiology 78:842–847, 1993.
377.
Glass PS, Doherty M, Jacobs JR, et al: Cp
50
for sufentanil. Anesthesiology 73:A378, 1990.
378.
Thomson IR, Henderson BT, Singh K, Hudson RJ:
Concentration-response relationships for fentanyl and sufentanil in patients undergoing
coronary artery bypass grafting. Anesthesiology 89:852–861, 1998.
379.
Marty J, Couderc E, Servin F, et al: Plasma concentration
of sufentanil required to suppress hemodynamic responses to noxious stimuli during
nitrous oxide anesthesia. Anesthesiology 69:A631, 1988.
380.
Patel SS, Spencer CM: Remifentanil. Drugs 52:417–427,
1996.
381.
Hogue CW Jr, Bowdle TA, O'Leary C, et al: A multicenter
evaluation of total intravenous anesthesia with remifentanil and propofol for elective
inpatient surgery. Anesth Analg 83:2792–85, 1996.
382.
Avramov MN, Smith I, White PF: Interactions between
midazolam and remifentanil during monitored anesthesia care. Anesthesiology 85:1283–1289,
1996.
383.
Sneyd JR, Whaley A, Dimpel HL, Andrews CJ: An
open, randomized comparison of alfentanil, remifentanil and alfentanil followed by
remifentanil in anaesthesia for craniotomy. Br J Anaesth 81:361–364, 1998.
384.
Fletcher D, Pinaud M, Scherpereel P, et al: The
efficacy of intravenous 0.15 versus 0.25 mg/kg intraoperative morphine for immediate
postoperative analgesia after remifentanil-based anesthesia for major surgery. Anesth
Analg 90:666–671, 2000.
385.
Kochs E, Cote D, Deruyck L, et al: Postoperative
pain management and recovery after remifentanil-based anaesthesia with isoflurane
or propofol for major abdominal surgery. Remifentanil Study Group. Br J Anaesth
84:169–173, 2000.
386.
Guignard B, Coste C, Costes H, et al: Supplementing
desflurane-remifentanil anesthesia with small-dose ketamine reduces perioperative
opioid analgesic requirements. Anesth Analg 95:103–108, 2002.
387.
Eltzschig HK, Schroeder TH, Eissler BJ, et al:
The effect of remifentanil or fentanyl on postoperative vomiting and pain in children
undergoing strabismus surgery. Anesth Analg 94:1173–1177, 2002.
388.
Calderon E, Pernia A, De Antonio P, et al: A
comparison of two constant-dose continuous infusions of remifentanil for severe postoperative
pain. Anesth Analg 92:715–771, 2001.
389.
Ausems ME, Vuyk J, Hug CC Jr, Stanski DR: Comparison
of a computer-assisted infusion versus intermittent bolus administration of alfentanil
as a supplement to nitrous oxide for lower abdominal surgery. Anesthesiology 68:851–861,
1988.
390.
Vinik HR, Bradley EL Jr, Kissin I: Triple anesthetic
combination: propofol-midazolam-alfentanil. Anesth Analg 78:354–358, 1994.
391.
Vuyk J, Lim T, Engbers FH, Burm AG, et al: The
pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery
in women. Anesthesiology 83:8–22, 1995.
392.
Stanski DR, Shafer SL: Quantifying anesthetic
drug interaction. Implications for drug dosing. Anesthesiology 83:1–5, 1995.
393.
Richards MJ, Skues MA, Jarvis AP, Prys Roberts
C: Total i.v. anaesthesia with propofol and alfentanil: Dose requirements for propofol
and the effect of premedication with clonidine. Br J Anaesth 65:157–163, 1996.
394.
Wuesten R, Van Aken H, Glass PS, Buerkle H: Assessment
of depth of anesthesia and postoperative respiratory recovery after remifentanil-
versus alfentanil-based total intravenous anesthesia in patients undergoing ear-nose-throat
surgery. Anesthesiology 94:211–217, 2001.
395.
Vuyk J, Hennis PJ, Burm AG, et al: Comparison
of midazolam and propofol in combination with alfentanil for total intravenous anesthesia.
Anesth Analg 71:645–650, 1990.
396.
Raza SM, Masters RW, Vasireddy AR, Zsigmond EK:
Haemodynamic stability with midazolam-sufentanil analgesia in cardiac surgical patients.
Can J Anaesth 35:518–525, 1988.
397.
Bell J, Sartain J, Wilkinson GA, Sherry KM: Propofol
and fentanyl anaesthesia for patients with low cardiac output state undergoing cardiac
surgery: comparison with high-dose fentanyl anaesthesia. Br J Anaesth 73:162–166,
1994.
398.
Benthuysen JL, Foltz BD, Smith NT, et al: Prebypass
hemodynamic stability of sufentanil-O2
, fentanyl-O2
, and morphine-O2
anesthesia during cardiac surgery: A comparison of cardiovascular profiles. J Cardiothorac
Anesth 12:749–757, 1988.
399.
Sanford TJ Jr, Smith NT, Dec Silver H, Harrison
WK: A comparison of morphine, fentanyl, and sufentanil anesthesia for cardiac surgery:
induction, emergence, and extubation. Anesth Analg 65:259–66, 1986.
400.
Weiss Bloom LJ, Reich DL: Haemodynamic responses
to tracheal intubation following etomidate and fentanyl for anaesthetic induction.
Can J Anaesth 39:780–785, 1992.
401.
Howie MB, Black HA, Romanelli VA, et al: A comparison
of isoflurane versus fentanyl as primary anesthetics for mitral valve surgery. Anesth
Analg 83:941–948, 1996.
402.
Walter RR, Kim YD, Macnamara TE, et al: Comparison
of isoflurane vs. fentanyl anesthesia in ligation of the patent ductus arteriosus
in premature infants. Anesth Analg 65:S165, 1986.
403.
Glenski JA, Friesen RH, Berglund NL, Henry DB:
Comparison of the cardiovascular effects of sufentanil, fentanyl, isoflurane and
halothane during pediatric cardiac surgery. Anesthesiology 65:A438, 1986.
404.
Duncan HP, Cloote A, Weir PM, et al: Reducing
stress responses in the pre-bypass phase of open heart surgery in infants and young
children: a comparison of different fentanyl doses. Br J Anaesth 84:556–564,
2000.
405.
Beilin B, Shavit Y, Hart J, et al: Effects of
anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity
in the perioperative period. Anesth Analg 82:492–497, 1996.
406.
Mantz J, Abi Jaoude F, Ceddaha A, et al: High-dose
alfentanil for myocardial revascularization: A hemodynamic and pharmacokinetic study.
J Cardiothorac Vasc Anesth 5:107–110, 1991.
407.
Jhaveri R, Joshi P, Batenhorst R, et al: Dose
comparison of remifentanil and alfentanil for loss of consciousness. Anesthesiology
87:253–259, 1997.
408.
Roekaerts PM, Gerrits HJ, Timmerman BE, de Lange
S: Continuous infusions of alfentanil and propofol for coronary artery surgery.
J Cardiothorac Vasc Anesth 9:362–3367, 1995.
409.
Howie MB, Smith DF, Reilley TE, et al: Postoperative
course after sufentanil or fentanyl anesthesia for coronary artery surgery. J Cardiothorac
Vasc Anesth 5:485–489, 1991.
410.
Sareen J, Hudson RJ, Rosenbloom M, Thomson IR:
Doseresponse to anaesthetic induction with sufentanil: Haemodynamic and electroencephalographic
effects. Can J Anaesth 44:19–25, 1997.
411.
Abrams JT, Horrow JC, Bennett JA, et al: Upper
airway closure: A primary source of difficult ventilation with sufentanil induction
of anesthesia. Anesth Analg 83:629–632, 1996.
412.
Jain U, Body SC, Bellows W, et al: Multicenter
study of target-controlled infusion of propofol-sufentanil or sufentanil-midazolam
for coronary artery bypass graft surgery. Multicenter Study of Perioperative Ischemia
(McSPI) Research Group. Anesthesiology 85:522–535, 1996.
413.
Russell D, Royston D, Rees PH, et al: Effect
of temperature and cardiopulmonary bypass on the pharmacokinetics of remifentanil.
Br J Anaesth 79:456–459, 1997.
414.
Michelsen LG, Holford NH, Lu W, et al: The pharmacokinetics
of remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary
bypass. Anesth Analg 93:1100–1105, 2001.
415.
Ahonen J, Olkkola KT, Verkkala K, et al: A comparison
of remifentanil and alfentanil for use with propofol in patients undergoing minimally
invasive coronary artery bypass surgery. Anesth Analg 90:1269–1274, 2000.
416.
Engoren M, Luther G, Fenn Buderer N: A comparison
of fentanyl, sufentanil, and remifentanil for fast-track cardiac anesthesia. Anesth
Analg 93:859–864, 2001.
417.
Duthie DJ, Rowbotham DJ, Wyld R, et al: Plasma
fentanyl concentrations during transdermal delivery of fentanyl to surgical patients.
Br J Anaesth 60:614–618, 1988.
418.
Sandler AN, Baxter AD, Katz J, et al: A double-blind,
placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic,
respiratory, and pharmacokinetic effects. Anesthesiology 81:1169–1180, 1994.
419.
Varvel JR, Shafer SL, Hwang SS, et al: Absorption
characteristics of transdermally administered fentanyl. Anesthesiology 70:928–934,
1989.
420.
Rowbotham DJ, Wyld R, Peacock JE, et al: Transdermal
fentanyl for the relief of pain after upper abdominal surgery. Br J Anaesth 63:56–59,
1989.
421.
Ashburn MA, Streisand J, Zhang J, et al: The
iontophoresis of fentanyl citrate in humans. Anesthesiology 82:1146–1153,
1995.
422.
Moa G, Zetterstrom H: Sublingual buprenorphine
as postoperative analgesic: A double-blind comparison with pethidine. Acta Anaesthesiol
Scand 34:68–71, 1990.
423.
Bell MD, Murray GR, Mishra P, et al: Buccal morphine—a
new route for analgesia? Lancet 1:71–73, 1985.
424.
Fisher AP, Vine P, Whitlock J, Hanna M: Buccal
morphine premedication. A double-blind comparison with intramuscular morphine.
Anaesthesia 41:1104–111, 1986.
425.
Weinberg DS, Inturrisi CE, Reidenberg B, et al:
Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 44:335–342,
1988.
426.
Stanley TH, Hague B, Mock DL, et al: Oral transmucosal
fentanyl citrate (lollipop) premedication in human volunteers. Anesth Analg 69:21–27,
1989.
427.
Streisand JB, Stanley TH, Hague B, et al: Oral
transmucosal fentanyl citrate premedication in children. Anesth Analg 69:28–34,
1989.
428.
Friesen RH, Lockhart CH: Oral transmucosal fentanyl
citrate for preanesthetic medication of pediatric day surgery patients with and without
droperidol as a prophylactic anti-emetic. Anesthesiology 76:46–51, 1992.
429.
Feld LH, Champeau MW, van Steennis CA, Scott JC:
Preanesthetic medication in children: A comparison of oral transmucosal fentanyl
citrate versus placebo. Anesthesiology 71:374–377, 1989.
430.
Goldstein Dresner MC, Davis PJ, Kretchman E, et
al: Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine,
diazepam, and atropine as preanesthetic medication in children with congenital heart
disease. Anesthesiology 74:28–33, 1991.
431.
Streisand JB, Varvel JR, Stanski DR, et al: Absorption
and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75:223–229,
1991.
432.
Dsida RM, Wheeler M, Birmingham PK, et al: Premedication
of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. Anesth
Analg 86:66–70, 1998.
433.
Ashburn MA, Fine PG, Stanley TH: Oral transmucosal
fentanyl citrate for the treatment of breakthrough cancer pain: A case report.
Anesthesiology 71:615–617, 1989.
434.
Henderson JM, Brodsky DA, Fisher DM, et al: Pre-induction
of anesthesia in pediatric patients with nasally administered sufentanil. Anesthesiology
68:671–675, 1988.
435.
Karl HW, Keifer AT, Rosenberger JL, et al: Comparison
of the safety and efficacy of intranasal midazolam or sufentanil for preinduction
of anesthesia in pediatric patients. Anesthesiology 76:209–215, 1992.
436.
Zedie N, Amory DW, Wagner BK, O'Hara DA: Comparison
of intranasal midazolam and sufentanil premedication in pediatric outpatients. Clin
Pharmacol Ther 59:341–348, 1996.
437.
Helmers JH, Noorduin H, Van Peer A, et al: Comparison
of intravenous and intranasal sufentanil absorption and sedation. Can J Anaesth
36:494–497, 1989.
438.
Abboud TK, Zhu J, Gangolly J, et al: Transnasal
butorphanol: a new method for pain relief in post-cesarean section pain. Acta Anaesthesiol
Scand 35:14–8, 1991.
439.
Zacny JP, Lichtor JL, Klafta JM, et al: The effects
of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers.
Anesth Analg 82:931–935, 1996.
440.
Striebel HW, Oelmann T, Spies C, et al: Patient-controlled
intranasal analgesia: A method for noninvasive postoperative pain management. Anesth
Analg 83:548–551, 1996.
441.
Chrubasik J, Wust H, Friedrich G, Geller E: Absorption
and bioavailability of nebulized morphine. Br J Anaesth 61:228–230, 1988.
442.
Worsley MH, MacLeod AD, Brodie MJ, et al: Inhaled
fentanyl as a method of analgesia. Anaesthesia 45:449–451, 1990.
443.
Hung OR, Whynot SC, Varvel JR, et al: Pharmacokinetics
of inhaled liposome-encapsulated fentanyl. Anesthesiology 83:277–284, 1995.
444.
Hanning CD, Vickers AP, Smith G, et al: The morphine
hydrogel suppository. A new sustained release rectal preparation. Br J Anaesth
61:221–227, 1988.
445.
Lundeberg S, Beck O, Olsson GL, Boreus LO: Rectal
administration of morphine in children. Pharmacokinetic evaluation after a single-dose.
Acta Anaesthesiol Scand 40:445–451, 1996.
446.
Simpson KH, Dearden MJ, Ellis FR, Jack TM: Premedication
with slow release morphine (MST) and adjuvants. Br J Anaesth 60:825–830, 1988.
447.
Banning AM, Schmidt JF, Chraemmer Jorgensen B,
Risbo A: Comparison of oral controlled release morphine and epidural morphine in
the management of postoperative pain. Anesth Analg 65:385–388, 1986.
448.
Derbyshire DR, Bell A, Parry PA, Smith G: Morphine
sulphate slow release. Comparison with i.m. morphine for postoperative analgesia.
Br J Anaesth 57:858–865, 1985.
449.
Hoskin PJ, Poulain P, Hanks GW: Controlled-release
morphine in cancer pain. Is a loading dose required when the formulation is changed?
Anaesthesia 44:897–901, 1989.
450.
Reuben SS, Connelly NR, Maciolek H: Postoperative
analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament
surgery. Anesth Analg 88:1286–1291, 1999.
